Using a special balloon to treat recurring benign bowel strictures

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the safety and effectiveness of GIE Medical's ProTractX3™ TTS drug-coated balloon (DCB) for patients suffering from recurrent benign bowel strictures. Participants will receive the DCB intervention after having undergone at least two previous dilations for their condition. The study aims to determine if this innovative approach can improve patient outcomes compared to standard treatments. Follow-up assessments will be conducted to monitor the results and any potential complications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 22
2. Diagnosis of symptomatic benign bowel stricture with at least 2 previous dilations.
3. Willing and able to complete protocol required follow up
4. Willing and able to provide written informed consent
5. Stricture length ≤ 5 cm

Exclusion Criteria:

1. Female subjects who are pregnant or breastfeeding or plan to get pregnant in next 12 months
2. Contraindication to endoscopy, anesthesia, or deep sedation.
3. Suspicion of malignant bowel stricture NOTE: Biopsy should be taken for every stricture during the initial endoscopy, however endoscopic balloon dilation may proceed without awaiting results if suspicion for malignancy is low in the opinion of the investigator.
4. Benign stricture due to extrinsic compression
5. Stricture is not amenable to standard balloon dilation (e.g. severe angulation, unable to pass guidewire, etc.)
6. Stricture complicated with abscess, fistula, perforation, leakage or varices
7. Stricture segment has moderate to severe active inflammation at the time of treatment. Moderate to severe inflammation is defined as any one of; ulcers \>0.5cm in diameter, ulcerated surface \>10%, affected (inflamed) surface \>50%, marked erythema, absent vascular pattern, significant friability, or erosions
8. Multiple clinically significant strictures unable to be treated with a single balloon (i.e. total segment length must be ≤5cm) NOTE: Clinically significant strictures include those that are unable to be passed by the endoscope.
9. Received steroid injections into target stricture in the last 8 weeks
10. Stricture is not able to be dilated to ≥15mm in small bowel or ≥18mm in large bowel
11. Diagnosis of metastatic cancer of any type that is not considered in remission or non-metastatic cancer that may require radiation treatment in the pelvic region (e.g. prostate cancer)
12. Suspected perforation of gastrointestinal tract
13. Active systemic infection
14. Allergy to paclitaxel
15. Severe coagulation disorders or current use of anticoagulant or antiplatelet medication that cannot be safely managed per relevant societal guidelines
16. Chronic systemic steroid use (defined as greater than 10 mg/day) for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use
17. Condition requiring treatment in urgent setting
18. Life expectancy of less than 24 months
19. Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety, such as recent myocardial infarction, severe pulmonary disease, bleeding diathesis, large thoracic aneurysm, pharyngeal or cervical deformity, etc.
20. Current participation in another pre-market drug or medical device clinical study unless in long term follow-up

Where it's running

• Honor Health
  Scottsdale, Arizona, United States Recruiting
• University of California, Irvine
  Irvine, California, United States Recruiting
• Gastro Care Institute
  Lancaster, California, United States Recruiting
• Cedars Sinai
  Los Angeles, California, United States Recruiting
• San Diego Gastroenterology
  San Diego, California, United States Recruiting
• University of Colorado Anschutz
  Aurora, Colorado, United States Recruiting

Study contacts

• Study coordinator: Erika Wang
• Email: wange@giemedical.com
• Phone: 0000000000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guselkumab vs Ustekinumab for stricturing Crohn's disease

  This study will follow adults with moderate-to-severe Crohn's disease and confirmed intestinal strictures to see if treatment with guselkumab or ustekinumab better controls obstructive symptoms and disease activity.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07444060

• Evaluating Ustekinumab for Treating Stricturing Crohn's Disease

  This study is testing if ustekinumab can help people with moderate-to-severe Crohn's disease who have blockages in their intestines feel better over a two-year period.

  Recruiting at 8 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Beijing, Beijing Municipality and 7 other locations · NCT05387031

• Using fluorescence to assess bowel health during emergency surgery

  This study is testing if a special dye can help surgeons see if the bowel is healthy during emergency surgery for patients with suspected bowel problems, to see if it leads to better outcomes and fewer follow-up surgeries.

  Recruiting at 5 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen, Capital Region and 4 other locations · NCT06322862

• Understanding the intestinal immune system in newborns and its role in gastrointestinal diseases

  This study looks at how the immune system in newborns develops and how it relates to serious gut problems like NEC and bowel atresia, by collecting samples from both preterm and term infants.

  Recruiting at 2 sites Copenhagen University Hospital, Rigshospitalet · Copenhagen and 1 other locations · NCT06092463

• Comparing stent treatments for chronic mesenteric ischemia

  This study is testing whether covered stents work better than bare metal stents for people with chronic mesenteric ischemia to see which one helps them more after a year.

  Recruiting Copenhagen University Hospital, Rigshospitalet · København Ø · NCT05244629

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.